Literature DB >> 12621157

Advanced glycation end products (AGE) inhibit scavenger receptor class B type I-mediated reverse cholesterol transport: a new crossroad of AGE to cholesterol metabolism.

Nobutaka Ohgami1, Akira Miyazaki, Masakazu Sakai, Akihiko Kuniyasu, Hitoshi Nakayama, Seikoh Horiuchi.   

Abstract

Advanced glycation end products (AGE) -modified proteins behave as active ligands for several receptors belonging to the scavenger receptor family. Scavenger receptor class B type I (SR-BI) was identified as the first high density lipoprotein (HDL) receptor that mediates selective uptake of HDL-cholesteryl esters (HDL-CE). This study investigated whether AGE proteins serve as ligands for SR-BI and affect SR-BI-mediated cholesterol transport using Chinese hamster ovary (CHO) cells overexpressing hamster SR-BI (CHO-SR-BI cells). [125I] AGE-bovine serum albumin (AGE-BSA) underwent active endocytosis and subsequent lysosomal degradation by CHO-SR-BI cells, indicating that SR-BI serves as an AGE receptor. SR-BI-mediated selective uptake of HDL-CE by CHO-SR-BI cells was efficiently inhibited by AGE-BSA although AGE-BSA had no effect on HDL binding to CHO-SR-BI cells. In addition, AGE-BSA significantly inhibited the efflux of [3H] cholesterol from CHO-SR-BI cells to HDL. These findings suggest the possibility that AGE proteins in the circulation interfere with the functions of SR-BI in reverse cholesterol transport by inhibiting the selective uptake of HDL-CE, as well as cholesterol efflux from peripheral cells to HDL, thereby accelerating diabetes-induced atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12621157     DOI: 10.5551/jat.10.1

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  16 in total

1.  Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data.

Authors:  Theodore Mazzone
Journal:  Circulation       Date:  2010-11-23       Impact factor: 29.690

Review 2.  Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease.

Authors:  Rai Ajit K Srivastava
Journal:  Mol Cell Biochem       Date:  2017-08-21       Impact factor: 3.396

3.  Life-style-induced metabolic derangement and epigenetic changes promote diabetes and oxidative stress leading to NASH and atherosclerosis severity.

Authors:  Rai Ajit K Srivastava
Journal:  J Diabetes Metab Disord       Date:  2018-11-29

4.  [Protein glycation as a pathological mechanism in diabetes].

Authors:  A Simm; A Navarrete-Santos; B Hofmann; H Bushnaq; N Nass
Journal:  Z Gerontol Geriatr       Date:  2012-02       Impact factor: 1.281

Review 5.  Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies.

Authors:  Theodore Mazzone; Alan Chait; Jorge Plutzky
Journal:  Lancet       Date:  2008-05-24       Impact factor: 79.321

6.  Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation.

Authors:  Karly C Sourris; Anna Watson; Karin Jandeleit-Dahm
Journal:  Handb Exp Pharmacol       Date:  2021

Review 7.  Diabetes and atherosclerosis: is there a role for hyperglycemia?

Authors:  Alan Chait; Karin E Bornfeldt
Journal:  J Lipid Res       Date:  2008-11-23       Impact factor: 5.922

8.  Advanced glycation end-products (AGEs) and functionality of reverse cholesterol transport in patients with type 2 diabetes and in mouse models.

Authors:  H Low; A Hoang; J Forbes; M Thomas; J G Lyons; P Nestel; L A Bach; D Sviridov
Journal:  Diabetologia       Date:  2012-05-10       Impact factor: 10.122

Review 9.  The association between metabolic syndrome components and the development of atherosclerosis.

Authors:  Anahita Aboonabi; Roselyn Rose' Meyer; Indu Singh
Journal:  J Hum Hypertens       Date:  2019-10-21       Impact factor: 3.012

Review 10.  Endothelial Cell Receptors in Tissue Lipid Uptake and Metabolism.

Authors:  Nada A Abumrad; Ainara G Cabodevilla; Dmitri Samovski; Terri Pietka; Debapriya Basu; Ira J Goldberg
Journal:  Circ Res       Date:  2021-02-04       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.